Gd(3+)-DTPA-DG: novel nanosized dual anticancer and molecular imaging agent.
about
Design, modeling, expression, and chemoselective PEGylation of a new nanosize cysteine analog of erythropoietin.Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects.Nanotechnology in medicine: from inception to market dominationEvaluating the effect of ultrasmall superparamagnetic iron oxide nanoparticles for a long-term magnetic cell labelingCellular uptake and imaging studies of glycosylated silica nanoprobe (GSN) in human colon adenocarcinoma (HT 29 cell line).Conjugation of glucosamine with Gd3+-based nanoporous silica using a heterobifunctional ANB-NOS crosslinker for imaging of cancer cellsDiethylentriaminepenta acetic acid glucose conjugates as a cell permeable iron chelator.In Vitro Evaluation of Gd(3+)-Anionic Linear Globular Dendrimer-Monoclonal Antibody: Potential Magnetic Resonance Imaging Contrast Agents for Prostate Cancer Cell Imaging.Nanobiotech in big pharma: a business perspective.The perception of nanotechnology and nanomedicine: a worldwide social media study.Gd(3+)-DTPA-Meglumine-Anionic Linear Globular Dendrimer G1: Novel Nanosized Low Toxic Tumor Molecular MR Imaging Agent.The impact of effective patents on future innovations in nanomedicine.Nanomaterials in the Prevention, Diagnosis, and Treatment of Mycobacterium Tuberculosis Infections.Development of 153Sm-DTPA-SPION as a theranostic dual contrast agents in SPECT/MRI.Biodistribution properties of cleistanthin A and cleistanthin B using magnetic resonance imaging in a normal and tumoric animal model.Cost-effectiveness of nanomedicine: the path to a future successful and dominant market?Breast cancer cells imaging by targeting methionine transporters with gadolinium-based nanoprobe
P2860
Q35090476-67F1D3FF-CCC7-4D62-BAEB-B0197CD371E1Q35786517-829160E1-6135-46BB-9D27-159461E6EFF6Q35852640-6CC9ECC6-5AC2-4AF8-97AB-089B595B2158Q36713791-023FEA8D-D746-46C1-923E-DD0B2C391400Q37125446-0E846177-E8EB-44C7-B5FE-9312EDF79915Q37216003-34546BF9-8E5D-4FBC-B0EB-4F4B3FCF0110Q37565866-7FB0D959-384A-4E8B-B1E1-27125650B042Q38881712-D42EBCFE-167D-44A6-A903-95B8D2FC3256Q38971524-BB034B08-742E-4072-8BCF-EA9CA1B14A1CQ39123699-7055155C-FC9A-43CC-A348-7894C0D4EDF4Q39174930-48055368-0298-40BA-8CFB-343F1CD512BBQ39649136-27BD4F89-D713-4AC7-8CEA-52B952B9955CQ41931571-FAD22C96-1F44-4C54-892E-8EEF171A94A2Q41962075-5319ACB5-F305-46F4-8BA1-546668906C0BQ42192792-18056A9A-69A9-4025-90FE-A1A27389BD4EQ48443740-0DE32E49-523E-45CB-A201-75F9A3A9D449Q57183283-39F0CD51-BE9D-4F3D-9126-055A3E7BDD0E
P2860
Gd(3+)-DTPA-DG: novel nanosized dual anticancer and molecular imaging agent.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Gd(3+)-DTPA-DG: novel nanosized dual anticancer and molecular imaging agent.
@en
type
label
Gd(3+)-DTPA-DG: novel nanosized dual anticancer and molecular imaging agent.
@en
prefLabel
Gd(3+)-DTPA-DG: novel nanosized dual anticancer and molecular imaging agent.
@en
P2093
P2860
P356
P1476
Gd(3+)-DTPA-DG: novel nanosized dual anticancer and molecular imaging agent.
@en
P2093
Abass Alavi
Ali Jabbari-Arabzadeh
Bita Mehravi
Masoud Ghorbani
Massoud Amanlou
Mehdi Abbasi
Mehdi Shafiee Ardestani
Mohammad Reza Aghasadeghi
Mohammad Shafiee Alavidjeh
Saeed Shanehsaz
P2860
P304
P356
10.2217/NNM.11.55
P407
P577
2011-04-11T00:00:00Z